Medication info
Cojarotane Plus F Tablet

Cojarotane Plus F Tablet

Prescription medicationTabletOral
Ingredient · strength
Losartan Potassium›100mg / 1 tabletHydrochlorothiazide›25mg / 1 tablet
Manufacturer / importer
Boryung Biopharma Co., Ltd.
Appearance
Pale yellow oval film-coated tablet
Packaging
Bottle - 30 tablets/bottle
Approval status
Active

MFDS item code 202004054 · Approved 2020.05.29

Summary

Main use
Treatment of hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
○ Adults The usual dose of this medicine is one tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. The maximum blood pressure-lowering effect generally occurs approximately 3 weeks after the start of treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, initiate treatment with this medicine when the desired effect has not been achieved with monotherapy. 1. Substitution therapy: A combination regimen of individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with one tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of one tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of one tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia even when their blood pressure is controlled at this dose: Treatment may be initiated with one tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. Thereafter, continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of one tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment The usual dose may be administered when creatinine clearance is 30 mL/min or higher. Use of loop diuretics rather than thiazide drugs is preferable in patients with more severe renal impairment; therefore, administration to these patients is not recommended. ○ Patients with hepatic impairment Administration to these patients is not recommended because this medicine cannot provide the initial dose of losartan potassium, 25 mg, for patients with hepatic impairment who require dosage adjustment.
Child dose
○ Children (under 18 years of age) Because there is no experience with use in children and adolescents, the losartan-hydrochlorothiazide combination product should not be administered to children or adolescents.

Ingredients

Manufacturer
Boryung Biopharma Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled with monotherapy

  • Hypertension
View approved original text

This medication is used in patients with hypertension who have difficulty controlling blood pressure with monotherapy.

How to take

Adult dose

○ Adults The usual dose of this medicine is one tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. The maximum blood pressure-lowering effect generally occurs approximately 3 weeks after the start of treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, initiate treatment with this medicine when the desired effect has not been achieved with monotherapy. 1. Substitution therapy: A combination regimen of individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with one tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of one tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of one tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia even when their blood pressure is controlled at this dose: Treatment may be initiated with one tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. Thereafter, continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of one tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment The usual dose may be administered when creatinine clearance is 30 mL/min or higher. Use of loop diuretics rather than thiazide drugs is preferable in patients with more severe renal impairment; therefore, administration to these patients is not recommended. ○ Patients with hepatic impairment Administration to these patients is not recommended because this medicine cannot provide the initial dose of losartan potassium, 25 mg, for patients with hepatic impairment who require dosage adjustment.

Child dose

○ Children (under 18 years of age) Because there is no experience with use in children and adolescents, the losartan-hydrochlorothiazide combination product should not be administered to children or adolescents.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. It should not be administered to patients with allergies to this medication or its components, those with severely impaired kidney function, specific electrolyte imbalances, or certain genetic lactase deficiency. Patients with hypotension, kidney or liver dysfunction, abnormal serum potassium levels, the elderly, or those with a history of diabetes or gout should use this medication with caution. Since this drug has a blood pressure-lowering effect, dizziness or drowsiness may occur in the initial stages of treatment, so caution is advised when driving or operating machinery. Electrolyte levels and kidney function should be regularly monitored through blood tests, and it is recommended to avoid concurrent use with potassium supplements or potassium-containing medications. This medication may make the skin more sensitive to sunlight, so sun exposure should be minimized, and if any abnormalities occur on the skin, a doctor should be consulted immediately. Side effects such as cough, headache, abdominal pain, muscle pain, and rash may occur, but most are mild and transient. Women who are pregnant or planning to become pregnant should consult a doctor, and it is important to consult a specialist before using it while breastfeeding. This medication lacks sufficient experience for use in children and adolescents and is not recommended for them. In cases of overdose, hypotension and arrhythmias may occur, so immediate medical attention is required, and treatment should be conducted appropriately according to the symptoms. Store this medication in its original packaging in a place out of reach of children.

Side effects

  • Abdominal pain
  • edema
  • swelling
  • palpitations
  • low back pain
  • dizziness
  • cough
  • sinusitis
  • upper respiratory infection
  • rash
Show 126 more
  • angioedema
  • skin desquamation
  • hemolysis
  • chest pain
  • facial edema
  • fever
  • orthostatic hypotension
  • syncope
  • angina pectoris
  • arrhythmia
  • cerebrovascular accident
  • hypotension
  • myocardial infarction
  • secondary AV block
  • loss of appetite
  • constipation
  • toothache
  • dry mouth
  • dyspepsia
  • flatulence
  • gastritis
  • vomiting
  • malaise
  • anemia
  • gout
  • arm pain
  • joint pain
  • arthritis
  • fibromyalgia
  • hip pain
  • joint swelling
  • knee pain
  • leg pain
  • muscle cramps
  • muscle weakness
  • musculoskeletal pain
  • myalgia
  • shoulder pain
  • muscle stiffness
  • anxiety
  • anxiety disorder
  • ataxia
  • confusion
  • depression
  • nightmares
  • sensory loss
  • insomnia
  • decreased libido
  • memory impairment
  • migraine
  • hypersensitivity
  • panic disorder
  • sensory disturbances
  • peripheral neuropathy
  • sleep disorder
  • drowsiness
  • tremor
  • dyspnea
  • epistaxis
  • nasal congestion
  • pharyngeal discomfort
  • respiratory congestion
  • rhinitis
  • venous sinus disorder
  • chest discomfort
  • alopecia
  • dermatitis
  • dry skin
  • petechiae
  • erythema
  • flushing
  • photosensitivity reaction
  • pruritus
  • sweating
  • urticaria
  • blurred vision
  • ocular pain
  • burning sensation
  • conjunctivitis
  • decreased vision
  • taste disturbances
  • tinnitus
  • erectile dysfunction
  • nocturia
  • urinary frequency
  • urinary tract infection
  • fatigue
  • pancreatitis
  • jaundice
  • sialadenitis
  • seizures
  • gastrointestinal irritation
  • aplastic anemia
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • purpura
  • necrotizing vasculitis
  • fever
  • pneumonia
  • pulmonary edema
  • acute respiratory distress syndrome
  • hyperglycemia
  • diabetes
  • muscle spasms
  • restlessness
  • renal failure
  • renal dysfunction
  • interstitial nephritis
  • Stevens-Johnson syndrome
  • erythema multiforme
  • toxic epidermal necrolysis
  • transient blurred vision
  • xanthopsia
  • acute myopia
  • acute closed-angle glaucoma
  • choroidal exudate
  • vasculitis
  • anaphylactic reaction
  • hepatitis
  • intestinal vascular edema
  • dry cough
  • erythema multiforme
  • hyperkalemia
  • hyponatremia
  • rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container that blocks light, and it is preferable to store it at a temperature between 1°C and 30°C at room temperature. Storing it this way can help maintain the effectiveness of the medication.

Appearance and packaging

Appearance

Pale yellow oval film-coated tablet

Package unit

Bottle - 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.